retatrutide triple agonist glp-1 gip glucagon receptor The Road towards Agonists: Glucagon-Like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide and - An Update Targeting GLP-1, GIP & GCG

The oral version was previously available for diabetes management (under the brand name Rybelsus), but this new FDA approval specifically authorizes a high-dose oral formulation for chronic weight management

The researchers examined electronic medical records for patients with a pregravid BMI of more than 30 who delivered at more than 20 weeks gestation

Gallup found that following a recorded peak high of around 40% in 2022, study results showed a modest decrease to 37% in 2025

Patients with autoimmune hypothyroidism who have appropriate indicationssuch as type 2 diabetes or obesity with weight-related comorbiditiesmay safely use these medications under medical supervision